media – Page 646 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Grand Challenge by Bill Gates against Universal Flu

In the pilot phase, individual grants would be provided which would range from $250,000 to $2 million over two years. An additional $10 million may be provided if project is promising in animal studies but that money won’t be the part of this funding round
- Source: Ddu
- 734
- May 18, 2018
flu influenza strains Researches
LifePlus announces glucose monitoring wearable

The company announced that the innovative product, whose technological details are not known yet, is undergoing clinical trials in five cities across the world. The patent-pending invention is based on open standards software and cloud-based analytics. The system gives users real-time notifications and cloud-based AI solutions.
- Source: Ddu
- 1,134
- May 18, 2018
Clinical Trials mHealth wearables
New rapid Rabies test- LN34; developed by U.S Center for Disease Control

Rabies takes nearly 60,000 lives each year; it is deadly if not treated early. Regions like Africa and Asia are at higher risk. LN34 is believed to make screening faster and better test to avoid the weeks-long series of shots now given to prevent the disease for the people exposed to potentially rabid. The test, done on suspect animals, can be run on platforms which are already used to screen for the flu, tuberculosis, and HIV.
- Source: Ddu
- 1,151
- May 18, 2018
New Approvals pharmaceutical rabies
Power of mHealth technology elucidated by telepsychiatrist

A mobile health app developed by Medici is used by Kim who has stated that the technology helps him make the right connect with patients. He can log on to his smartphone or iPad when at home and make a HIPAA-compliant connection with concerned persons impacted by crisis or who would turn to medication.
- Source: Ddu
- 881
- May 18, 2018
digital health Market Views mHealth
Discovery of anti-stroke compound

A research team led by Yokohama City University and Toyama Chemical Co Ltd in Japan has developed a small compound named edonerpic maleate that showed enhanced recovery of motor function after brain damage in animal trials.
- Source: Ddu
- 754
- May 18, 2018
Clinical Trials Researches stroke
Apple health record app can disrupt the health data industry

iPhone maker Apple is all set to disrupt the conventionalities of medical data storage methodologies. The company has announced the development of a new health record app, a new standard that has been adopted by many big companies for transferring records across scattered systems. Apple is all set to break the traditional systems of several silos in which medical data is stored.
- Source: drugdu
- 856
- May 18, 2018
Company Insight digital health mHealth
Marico to focus on the healthcare startup

FMCG major Marico has announced that it will be investing in Revolutionary Fitness, owner of health and fitness app Revofit. The company stated that it will acquire around 22.5 percent stake in the health startup.
- Source: Ddu
- 779
- May 18, 2018
Company Insight health apps mHealth
EIP Pharma bags $20.5M to support Alzheimer’s drug through phase 2

EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
- Source: Ddu
- 689
- May 18, 2018
Alzheimer's disease Clinical Trials
R&D for organ-on-a-chip tech by AstraZeneca and Emulate.

AstraZeneca has collaborated with Emulate integrate an organ-on-a-chip technology into the R&D program of the pharma giant. It is meant to expedite the technology’s development within the company.
- Source: Ddu
- 887
- May 17, 2018
AstraZeneca Researches
AbbVie pressurized to keep low price for Imbruvica formula

This year AbbVie launched Imbruvica, a single tablet for blood cancer treatment. It has been designed as a convenient therapy measure for patients who used the old tablets as often as four times a day. Adapting the new single tablet in their treatment regimens will prove to be an expensive proposition for some patients as the new tablet comes with a price tag of $400 each, triple the cost of the older tablets.
- Source: Ddu
- 1,316
- May 17, 2018
AbbVie Company Insight pharma pharmaceutical

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.